Biomarker selection - Biomarkable

Wiltfang J, Lewczuk P, Riederer P, Grünblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselmann H, Henkel AW, Kornhuber J, Blennow K. Consensus paper of the WFSBP task force on biological markers of dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychatr 2005;6:69-84.
Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, Blennow K, Vanmechelen E. Amino-Truncated ß-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment. Clin Chem 2005; 51:1650-1660.
Saez-Valero J, Fodero LR, Sjögren M, Andreasen N, Amici S, Gallai V, Vanderstichele H, Vanmechelen E, Parnetti L, Blennow K, Small DH. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer’s disease. J Neurosci Res 2003; 72: 520-526.
Arai H, Higuchi M, Okamura N, Morikawa Y-I, Higuchi S, Iwatsubo T, Vanmechelen E, Vanderstichele H, Trojanowski JQ, Sasaki H. Molecular and biological markers for diagnosing and monitoring the progression of Alzheimer’s disease. Neurobiology of Alzheimer’s disease, edited by Dawbarn D and Allen SJ, Oxford University Press, New York, 2001, Chapter 12, 294-311, Diagnosis of Alzheimer’s.
Andreasen N, Gottfries J, Vanmechelen E, Vanderstichele H, Davidsson P, Rosengren L, Blennow K. Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and ß-amyloid metabolism in Alzheimer’s disease. J Neurol Neurosurg Psychiatr 2001; 71: 557-558.